A real-world pharmacovigilance study of FDA adverse event reporting system events for Lutetium-177-PSMA-617.
Humans
Pharmacovigilance
United States
Lutetium
/ adverse effects
Male
Adverse Drug Reaction Reporting Systems
Prostatic Neoplasms, Castration-Resistant
/ drug therapy
United States Food and Drug Administration
Heterocyclic Compounds, 1-Ring
/ adverse effects
Dipeptides
/ adverse effects
Bayes Theorem
Databases, Factual
Prostate-Specific Antigen
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
28 10 2024
28 10 2024
Historique:
received:
18
03
2024
accepted:
25
10
2024
medline:
29
10
2024
pubmed:
29
10
2024
entrez:
29
10
2024
Statut:
epublish
Résumé
Lutetium-177(
Identifiants
pubmed: 39468291
doi: 10.1038/s41598-024-77889-3
pii: 10.1038/s41598-024-77889-3
doi:
Substances chimiques
Lutetium
5H0DOZ21UJ
Heterocyclic Compounds, 1-Ring
0
Dipeptides
0
Pluvicto
0
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
25712Subventions
Organisme : Tianjin Municipal Health Commission
ID : TJSJMYXYC-D2-026
Informations de copyright
© 2024. The Author(s).
Références
Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024 [J]. CA: a cancer journal for clinicians, 74(1): 12–49 (2024). https://doi.org/10.3322/caac.21820
Desai, K., Mcmanus, J. M. & Sharifi, N. Hormonal therapy for prostate Cancer [J]. Endocr. Rev. 42 (3), 354–373. https://doi.org/10.1210/endrev/bnab002 (2021).
doi: 10.1210/endrev/bnab002
pubmed: 33480983
pmcid: 8152444
Ge, R. et al. Epigenetic modulations and lineage plasticity in advanced prostate cancer [J]. Annals oncology: official J. Eur. Soc. Med. Oncol. 31 (4), 470–479. https://doi.org/10.1016/j.annonc.2020.02.002 (2020).
doi: 10.1016/j.annonc.2020.02.002
Banerjee, S., Pillai, M. R. & Knapp, F. F. Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications [J]. Chem. Rev. 115 (8), 2934–2974. https://doi.org/10.1021/cr500171e (2015).
doi: 10.1021/cr500171e
pubmed: 25865818
Violet, J. et al. Dosimetry of (177)Lu-PSMA-617 in metastatic castration-resistant prostate cancer: Correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes [J. J. Nucl. Med. Off. Publ. Soc. Nuclear Med. 60 (4), 517–523. https://doi.org/10.2967/jnumed.118.219352 (2019).
doi: 10.2967/jnumed.118.219352
Current, K. et al. Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity [J]. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 26 (12), 2946–2955. https://doi.org/10.1158/1078-0432.Ccr-19-1485 (2020).
doi: 10.1158/1078-0432.Ccr-19-1485
Afshar-Oromieh, A. et al. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions [J]. J. Nucl. Med. Off. Publ. Soc. Nuclear Med. 56 (11), 1697–1705. https://doi.org/10.2967/jnumed.115.161299 (2015).
doi: 10.2967/jnumed.115.161299
Patell, K. et al. Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review [J]. Expert Rev. Anticancer Ther. 23 (7), 731–744. https://doi.org/10.1080/14737140.2023.2213892 (2023).
doi: 10.1080/14737140.2023.2213892
pubmed: 37194261
Sartor, O. et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer [J]. N. Engl. J. Med. 385 (12), 1091–1103. https://doi.org/10.1056/NEJMoa2107322 (2021).
doi: 10.1056/NEJMoa2107322
pubmed: 34161051
pmcid: 8446332
Dhodapkar, M. M. et al. Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008-19: cross sectional study [J]. BMJ (Clinical Res. ed), 379, e071752. https://doi.org/10.1136/bmj-2022-071752 (2022).
Michel, C. et al. Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles? [J]. Clin. Drug Investig. 37 (5), 415–422. https://doi.org/10.1007/s40261-017-0503-6 (2017).
doi: 10.1007/s40261-017-0503-6
pubmed: 28224371
Weaver, J. et al. Finding, evaluating, and managing drug-related risks: approaches taken by the US Food and Drug Administration (FDA) [J]. Dermatol. Ther. 22 (3), 204–215. https://doi.org/10.1111/j.1529-8019.2009.01233.x (2009).
doi: 10.1111/j.1529-8019.2009.01233.x
pubmed: 19453344
Psaty, B. M. & Siscovick, D. S. Minimizing bias due to confounding by indication in comparative effectiveness research: the importance of restriction [J]. Jama. 304 (8), 897–898. https://doi.org/10.1001/jama.2010.1205 (2010).
doi: 10.1001/jama.2010.1205
pubmed: 20736474
Bate, A. & Evans, S. J. Quantitative signal detection using spontaneous ADR reporting [J]. Pharmacoepidemiol. Drug Saf. 18 (6), 427–436. https://doi.org/10.1002/pds.1742 (2009).
doi: 10.1002/pds.1742
pubmed: 19358225
Elisabetta, P. et al. Data Mining Techniques in Pharmacovigilance: Analysis of the Publicly Accessible FDA Adverse Event Reporting System (AERS) [M]//ADEM K. Data Mining Applications in Engineering and Medicine. Rijeka; IntechOpen. : Ch. 12. (2012). https://doi.org/10.5772/50095
Huynh-Le, M. P. et al. Adverse Events Associated With Radium-223 in Metastatic Prostate Cancer: Disproportionality Analysis of FDA Data Reflecting Worldwide Utilization [J]. Clin. Genitourin. Cancer, 18(3): 192–200e192. https://doi.org/10.1016/j.clgc.2019.11.017 (2020).
Van Puijenbroek, E. P. et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions [J]. Pharmacoepidemiol. Drug Saf. 11 (1), 3–10. https://doi.org/10.1002/pds.668 (2002).
doi: 10.1002/pds.668
pubmed: 11998548
Evans, S. J., Waller, P. C. & Davis, S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports [J]. Pharmacoepidemiol. Drug Saf. 10 (6), 483–486. https://doi.org/10.1002/pds.677 (2001).
doi: 10.1002/pds.677
pubmed: 11828828
Dumouchel, W. Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System [J]. Am. Stat. 53 (3), 177–190. https://doi.org/10.1080/00031305.1999.10474456 (1999).
doi: 10.1080/00031305.1999.10474456
Bate, A. et al. A Bayesian neural network method for adverse drug reaction signal generation [J]. Eur. J. Clin. Pharmacol. 54 (4), 315–321. https://doi.org/10.1007/s002280050466 (1998).
doi: 10.1007/s002280050466
pubmed: 9696956
Schaeffer, E. M. et al. NCCN Guidelines® Insights: Prostate Cancer, Version 3.2024 [J]. J. Natl. Compr. Cancer Network: JNCCN. 22 (3), 140–150. https://doi.org/10.6004/jnccn.2024.0019 (2024).
doi: 10.6004/jnccn.2024.0019
pubmed: 38626801
Tilki, D. et al. Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer [J]. Eur. Urol. 86 (2), 164–182. https://doi.org/10.1016/j.eururo.2024.04.010 (2024).
doi: 10.1016/j.eururo.2024.04.010
pubmed: 38688773
Chi, K. N. et al. Safety Analyses of the Phase 3 VISION Trial of [(177)Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer [J]. Eur. Urol. 85 (4), 382–391. https://doi.org/10.1016/j.eururo.2023.12.004 (2024).
doi: 10.1016/j.eururo.2023.12.004
pubmed: 38185538
Almuradova, E. et al. The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study [J]. Int. J. Cancer. 154 (4), 692–700. https://doi.org/10.1002/ijc.34749 (2024).
doi: 10.1002/ijc.34749
pubmed: 37818966
Hofman, M. S. et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial [J]. Lancet (London England). 397 (10276), 797–804. https://doi.org/10.1016/s0140-6736(21)00237-3 (2021).
doi: 10.1016/s0140-6736(21)00237-3
pubmed: 33581798
Zhang, X. Interactions between cancer cells and bone microenvironment promote bone metastasis in prostate cancer [J]. Cancer Commun. (London England). 39 (1), 76. https://doi.org/10.1186/s40880-019-0425-1 (2019).
doi: 10.1186/s40880-019-0425-1
Kabasakal, L. et al. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer [J]. Eur. J. Nucl. Med. Mol. Imaging. 42 (13), 1976–1983. https://doi.org/10.1007/s00259-015-3125-3 (2015).
doi: 10.1007/s00259-015-3125-3
pubmed: 26227531
Fisher, D. R. Perspectives on Internal Dosimetry for Optimized Radionuclide Therapy [J]. Cancer Biother. Radiopharm. 37 (3), 161–163. https://doi.org/10.1089/cbr.2021.0318 (2022).
doi: 10.1089/cbr.2021.0318
pubmed: 34569812
Fizazi, K. et al. Health-related quality of life and pain outcomes with [(177)Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial [J]. Lancet Oncol. 24 (6), 597–610. https://doi.org/10.1016/s1470-2045(23)00158-4 (2023).
doi: 10.1016/s1470-2045(23)00158-4
pubmed: 37269841
pmcid: 10641914
Sakaeda, T. et al. Data mining of the public version of the FDA Adverse Event Reporting System [J]. Int. J. Med. Sci., 10(7): 796–803. https://doi.org/10.7150/ijms.6048 (2013).
Patnaik, S. et al. Metastatic spinal cord compression [J]. British journal of hospital medicine (London, England: 2020, 81(4): 1–10. DOI: (2005). https://doi.org/10.12968/hmed.2019.0399
Fox, P. C. Acquired salivary dysfunction. Drugs and radiation [J]. Ann. N. Y. Acad. Sci. 842, 132–137. https://doi.org/10.1111/j.1749-6632.1998.tb09641.x (1998).
doi: 10.1111/j.1749-6632.1998.tb09641.x
pubmed: 9599303